Progesterone added to chemo for adrenal cancer that spread
Part of Cancer, Hormones & metabolism clinical trials.
This Phase 2 trial tests whether adding progesterone to standard chemotherapy improves outcomes for people with adrenal cortical carcinoma (ACC) that is locally advanced or has spread and cannot be removed with surgery. It also checks whether the treatment is safe and tolerable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of adrenal cortical carcinoma (ACC) based on pathology (a tissue test).
- Your ACC is advanced or metastatic and cannot be fully removed by curative surgery.
- You are at least 18 years old and able to do daily activities at a moderate level (ECOG 0–2).
- Your blood counts and organ tests (kidney, liver, and heart) must meet study safety thresholds.
- You can use effective birth control, and your expected health outlook is more than 3 months.
- You must be able to follow the study schedule and sign informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a type of immunotherapy (pembrolizumab) to targeted radiation can help people with adrenal cancer that has spread to the liver. It aims to shrink tumors and slow the cancer's growth.
This Phase 2 trial studies pembrolizumab (an immune therapy) in people with advanced adrenocortical carcinoma that has progressed despite prior chemotherapy. It aims to shrink tumors or slow growth by helping the immune system recognize the cancer.
This trial tests a combination of an immunotherapy drug (PD-1 antibody) and radiation therapy for people with adrenal cortical carcinoma that has come back or spread and can't be removed with surgery. The goal is to see if this combination can help shrink or control the cancer when other treatments have stopped working.
This trial tests whether combining camrelizumab (an immune treatment) with apatinib (a targeted drug) can shrink recurrent or metastatic adrenal cancer after standard treatment didn’t work. It may help some people control tumor growth when other treatments have already been tried.
This trial tests a drug called cemiplimab as a maintenance treatment for patients with adrenocortical cancer whose disease did not worsen after initial chemotherapy. It is designed to keep the cancer from coming back.
This study looks at whether giving mitotane after surgery (and possibly adding cisplatin/etoposide chemotherapy) helps prevent adrenal cancer from coming back. It is for people with stage I–III adrenal cortical cancer who have a high risk of relapse after their tumor was removed.
Hear when a new Adrenocortical Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.